CTOs on the Move

myMatrixx

www.mymatrixx.com

 
myMatrixx is a full-service pharmacy benefit management (PBM) and ancillary services company focused on workers’ compensation. By combining advanced technology and proactive clinical management throughout the claims process, myMatrixx delivers a Fast, Simple, Effective solution with proven Results. Founded in 2001 by Steven MacDonald, an industry veteran in workers’ compensation, myMatrixx began as a pharmacy benefit manager. Today services include a corporately-owned and operated mail service pharmacy with compounding, ancillary services and DME, and proactive clinical programs. With a focus on workers’ compensation, myMatrixx serves self-insured employers, third party administrators, managed care companies, as well as workers’ compensation and auto insurance ...
  • Number of Employees: 100-250
  • Annual Revenue: $50-100 Million
  • www.mymatrixx.com
  • 5706 Benjamin Center Dr Ste 103
    Tampa, FL USA 33634
  • Phone: 813.425.9655

Executives

Name Title Contact Details

Similar Companies

ASP Global

We help you reach your savings targets and your patient experience goals by designing and delivering supplies and patient care products.

SpaLab

SpaLab is a San Marcos, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Elabscience

Elabscience is a biotech corporation that specializes in laboratory reagents for life science research, including ELISA kits, FCM antibodies, biochemical kits, antibodies, and proteins.

uniPHARM Wholesale Drugs

uniPHARM Wholesale Drugs Ltd. is a Richmond, BC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

La Jolla Pharmaceutical

La Jolla Pharmaceutical Company is a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases. The Company has several product candidates in development. LJPC-501 is La Jolla`s proprietary formulation of angiotensin II for the potential treatment of catecholamine-resistant hypotension. LJPC-401 is La Jolla`s novel formulation of hepcidin for the potential treatment of conditions characterized by iron overload, such as hereditary hemochromatosis, beta thalassemia, sickle cell disease and myelodysplastic syndrome. LJPC-30S is our next-generation gentamicin derivative program that is focused on therapeutics for the potential treatment of serious bacterial infections as well as rare genetic disorders, such as cystic fibrosis and Duchenne muscular dystrophy.